Barclays upgrades Croda International stock rating to Overweight despite lowering price target

Barclays upgraded Croda International to Overweight from Equalweight, lowering its price target to GBP31.00 but still implying 16% upside, citing trough valuations, expanding cost discipline, and the potential for activist-driven strategic action following a ~70% share price decline since late 2021. This upgrade, echoed by JPMorgan, suggests a potential inflection point for the specialty chemicals firm, driven by valuation and activist engagement despite mixed analyst sentiment, including a 'Reduce' rating from Kepler Cheuvreux.

Analysis

Croda International (CRDA) has received a notable upgrade to Overweight from Equalweight by Barclays, positioning the company as a potential turnaround story. This upgrade is significant as it occurs despite a lowered price target to GBP31.00 and follows a severe ~70% share price decline from its late 2021 peak, a period during which the FTSE100 gained 26%. The investment thesis from Barclays is predicated on a valuation at trough levels, evidence of expanding cost discipline, and the entry of activist investor Standard Latitude, which is seen as a catalyst for more decisive strategic action, including potential divestments. This view is partially echoed by JPMorgan, which also upgraded the stock to Overweight on valuation grounds with a GBP36.00 price target. However, the outlook is not universally positive. Kepler Cheuvreux initiated coverage with a Reduce rating and a GBP28.40 target, citing a significant decline in earnings and margins relative to industry peers. Despite the stock's 33.5% fall over the past year, Croda maintains fundamental strengths, including a strong liquidity position with a current ratio of 2.07 and a consistent 34-year dividend payment history, which may provide a degree of support.

Key Decisions for Investors

• Investors may consider the upgrades from Barclays and JPMorgan as a signal to re-evaluate Croda as a value play, predicated on the low valuation and the potential for an activist-driven turnaround.
• It is crucial to monitor for specific strategic actions from management and the activist investor, particularly regarding cost discipline and potential divestments, as these are the key catalysts underpinning the bull thesis.
• The conflicting analyst ratings, with Kepler Cheuvreux's 'Reduce' highlighting deteriorating fundamentals, warrant a cautious approach, and investors should weigh the potential for a value trap against the turnaround opportunity.